NeurAxis (NRXS) investor relations material

Conference overview

• The event focused on small and microcap public companies, with presentations and Q&A sessions for investors.

• The next conference is scheduled for December 8-9, 2026.

• Attendees could submit questions live during presentations.

Company highlights and strategy

• First-to-market med tech company specializing in neuromodulation therapies for GI disorders, especially in pediatrics.

• Achieved Category I CPT code effective January 2026, enabling scalable billing and insurance coverage.

• Over 100 million covered lives and strong insurance policy momentum, especially in pediatric markets.

• Expanding into the VA system via FSS contract and conducting a multi-site adult RCT.

Market opportunity and product details

• Serviceable available market estimated at $22 billion, with $8 billion in pediatrics.

• Only FDA-cleared treatment for functional dyspepsia in children and adults, with minimal competition.

• Device protocol involves four disposable devices per patient over four weeks, priced at $1,200 each.

• Device redesign expected in early 2027 to enhance usability and appeal.